LON:IMM - ImmuPharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 5.52
▲ +0.216 (4.08%)

This chart shows the closing price for IMM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmuPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMM

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ImmuPharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a -100.00% upside from the last price of GBX 5.52.

This chart shows the closing price for IMM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in ImmuPharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/7/2018Northland SecuritiesReiterated RatingCorporate
9/26/2018Northland SecuritiesReiterated RatingCorporate
9/7/2018Northland SecuritiesReiterated RatingCorporate
6/14/2018Northland SecuritiesDowngradeCorporate
4/17/2018Northland SecuritiesReiterated RatingBuy
4/16/2018Berenberg BankReiterated RatingBuy
3/23/2018Northland SecuritiesReiterated RatingBuyGBX 181
1/24/2018Northland SecuritiesReiterated RatingBuyGBX 181
1/18/2018Northland SecuritiesReiterated RatingBuyGBX 181
12/21/2017Northland SecuritiesReiterated RatingBuyGBX 181
12/21/2017FinnCapReiterated RatingBuyGBX 237
12/12/2017FinnCapInitiated CoverageBuyGBX 237
11/2/2017Northland SecuritiesReiterated RatingBuyGBX 181
10/4/2017Northland SecuritiesReiterated RatingBuyGBX 181
9/27/2017Northland SecuritiesReiterated RatingBuyGBX 181
9/21/2017Northland SecuritiesReiterated RatingBuyGBX 181
6/30/2017Northland SecuritiesBoost Price TargetBuyGBX 171 ➝ GBX 181
6/7/2017Northland SecuritiesReiterated RatingBuyGBX 171
6/1/2017Northland SecuritiesReiterated RatingBuyGBX 171
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/26/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
ImmuPharma logo
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 5.52
Low: 5.32
High: 5.52

50 Day Range

MA: GBX 6.22
Low: 5.30
High: 8.04

52 Week Range

Now: GBX 5.52
Low: 4.80
High: 10.90

Volume

37,033 shs

Average Volume

1,248,308 shs

Market Capitalization

£15.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmuPharma?

The following equities research analysts have issued reports on ImmuPharma in the last twelve months:
View the latest analyst ratings for IMM.

What is the current price target for ImmuPharma?

0 Wall Street analysts have set twelve-month price targets for ImmuPharma in the last year.
View the latest price targets for IMM.

What is the current consensus analyst rating for ImmuPharma?

ImmuPharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMM.

How do I contact ImmuPharma's investor relations team?

ImmuPharma's physical mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company's listed phone number is +44-20-71524080. The official website for ImmuPharma is www.immupharma.org. Learn More about contacing ImmuPharma investor relations.